Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $27,213.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 564 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $48.25, for a total value of $27,213.00. Following the transaction, the senior vice president directly owned 2,903 shares of the company's stock, valued at $140,069.75. This trade represents a 16.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Thursday, July 3rd, Jolanda Howe sold 477 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $49.08, for a total value of $23,411.16.

Mirum Pharmaceuticals Trading Up 1.7%

MIRM stock traded up $0.84 during trading on Friday, hitting $49.93. The company had a trading volume of 216,684 shares, compared to its average volume of 464,541. The company has a quick ratio of 3.04, a current ratio of 3.22 and a debt-to-equity ratio of 1.32. The firm has a 50-day moving average price of $46.46 and a 200-day moving average price of $45.56. Mirum Pharmaceuticals, Inc. has a 12 month low of $34.47 and a 12 month high of $54.23. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -31.01 and a beta of 0.97.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The firm had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same quarter in the previous year, the business earned ($0.54) EPS. The business's quarterly revenue was up 61.2% compared to the same quarter last year. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently bought and sold shares of MIRM. CWM LLC lifted its position in Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company's stock worth $27,000 after buying an additional 428 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $35,000. Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at $42,000.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Wall Street Zen lowered Mirum Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday. Raymond James Financial restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. Finally, JMP Securities raised their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $65.50.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.